New stem cell transplant approach shows promise for blood cancer patients without full matches

NCT ID NCT03480360

Completed Disease control Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemotherapy, radiation, and drugs to prevent rejection and graft-versus-host disease. The study tracked survival, engraftment, and immune recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant with chemotherapy and radiation
What this could lead to: If successful, this approach could offer a safer, more accessible transplant option for people with blood cancers who lack a fully matched donor.
What could go wrong: This is a small, single-center trial with only 21 participants. The transplant carries serious risks, including graft-versus-host disease, infection, and organ damage. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive classic Hodgkin lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive lymphoma lymphoma, non-Hodgkin, familial myelodysplastic syndrome myelodysplastic syndrome with excess blasts myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm non-Hodgkin lymphoma plasma cell myeloma plasma cell neoplasm primary myelofibrosis Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC MYELOID LEUKEMIA LYMPHOMA LYMPHOMA, NON-HODGKIN MYELODYSPLASIA MYELOFIBROSIS MYELOPROLIFERATIVE DISORDER PLASMA CELL DISORDER

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center

Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.